Evidence map›Paper›PMID 32060226›Full record

ArticleCancer research2020

Build-a-Mouse: Melanoma Modeling Picks up Speed.

Andres Thorkelsson, Glenn Merlino, Helen Michael

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Andres ThorkelssonLaboratory of Cancer Biology and Genetics, Center for Cancer Research, NCI, Bethesda, Maryland.
Glenn MerlinoLaboratory of Cancer Biology and Genetics, Center for Cancer Research, NCI, Bethesda, Maryland.
Helen MichaelLaboratory of Cancer Biology and Genetics, Center for Cancer Research, NCI, Bethesda, Maryland. helen.michael@nih.gov.

Funding

Genetically Engineered Mouse Models to Study RTK Function in MelanomaZIABC008756 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MERLINO, GLENN T. · 2009 to 2024
$17.7M
6 · The paper itself

Abstract

The study by Bok and colleagues in this issue introduces a new paradigm for generating new mouse models for melanoma research. Genetically engineered mouse models (GEMM) have been crucial for understanding tumor initiation and modeling potential therapies, but are time consuming to create. Bok and colleagues generated and validated high-contribution chimeric GEMM models using common melanoma GEMMs as a starting point and added additional CRISPR, Cre-inducible, and Dox-inducible alleles. This rapid method for generating new models has the potential to revolutionize mouse modeling for melanoma.

Indexed as

Embryonic Stem CellsAnimalsClustered Regularly Interspaced Short Palindromic RepeatsDisease Models, AnimalMelanomaMice

Identifiers

PMID32060226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.